Abstract: Objective:To compare the clinical efficacy and safety of ticagrelor and clopidogrel that applied in the antiplatelet therapy in the patients after coronary artery bypass grafting(CABG),and to provide a more rational strategy for antiplatelet therapy. Methods:A total of 260 patients underwent CABG were selected randomly and divided into ticagrelor group (n=129) and clopidogrel group (n=131). The patients in ticagrelor group were given ticagrelor 90 mg·d^-1 and aspirin 100 mg·d^-1,and the patients in clopidogrel group were given clopidogrel 75 mg·d^-1 and aspirin 100 mg·d^-1.After 12 months of follow-up,the major adverse cardiovascular events (MACE) and the adverse events related to safety were collected such as cardiovascular death,non-cardiovascular death,recurrent myocardial infarction,re-admission to hospital due to recurrent unstable angina pectoris and heart failure,dyspnea,bleeding,etc.The data was analyzed by statistical method. Results:In this study,241 patients finished the follow-up plan,including 122 patients in ticagrelor group and 119 patients in clopidogrel group.In the aspect of MACE,there were 10 cases (8.2%) in ticagrelor group and 19 cases (16.0%) in clopidogrel group; the difference between two groups was not statistically significant (P>0.05). In ticagrelor group,one patient (0.8%) came back to hospital again because of heart failure,and six cases (5.0%) in clopidogrel group; the difference between two groups was statistically significant (P<0.05). In the safety related adverse events aspect,there were 27 cases (22.1%) in ticagrelor group and 17 cases (14.3%) in clopidogrel group; the difference between two groups was not statistically significant (P>0.05). Conclusion: The efficacy and safety of ticagrelor applicated in the patients after CABG are not different compared with clopidogrel,which can be used as the antiplatelet strategy after CABG.

Key words: saftey, Ticagrelor, Clopidogrel, retrospective study, efficacy, coronary artery bypass graft